What psilocybin teaches us about therapy: measurable brain and well-being effects

What psilocybin research can teach us about therapy

In recent years, there has been a great deal of attention paid to psychedelics in relation to therapy. This is sometimes accompanied by high expectations, whereas the scientific picture is actually being built up step by step. A recent study, published in Nature Communications, is a good example of that: researchers looked at what changes in the brain and in self-reports of well-being after a first psilocybin experience in people who had never used psychedelics.

This type of work is not “proof that psilocybin is therapy” for a specific condition. It is mechanistic research: it attempts to understand what measurably changes, when that happens, and how those changes might relate to psychological processes that are also relevant in therapy, such as insight, flexibility, and emotional processing. In this article, we outline the findings, place them in context, and translate the key lessons into a therapeutic perspective, without medical claims or promises.

The study in brief: small, controlled, and exploratory

The researchers studied 28 healthy participants who were “psychedelic-naive,” meaning they had never had a psychedelic experience before. In an exploratory, placebo-controlled design, participants were first given 1 mg of psilocybin (as the active placebo) and, at a later time, 25 mg of psilocybin (a high dose). This is important: 1 mg can produce mild effects but is generally not comparable to a full psychedelic experience; 25 mg is.

What makes this study unique is the breadth of the measurements. EEG (brain waves), fMRI (functional brain activity), MRI (structure), and DTI (white matter tracts, connections in the brain) were used. Additionally, participants reported psychological outcomes such as well-being, cognitive flexibility, and psychological insight at various time points, up to a month later.

Because this involves a small group of healthy participants, caution is necessary. The results are interesting for understanding mechanisms, but in themselves say nothing definitive about therapeutic efficacy in people with symptoms, let alone about long-term or repeated sessions.

Acute brain dynamics: more “entropy” and less alpha activity

One of the clearest findings occurred during the acute action of 25 mg of psilocybin. Approximately 1 to 2 hours after ingestion, the researchers observed an increase in “brain entropy,” measured by Lempel-Ziv complexity, and a decrease in alpha activity in the EEG.

In plain language: brain activity temporarily became less predictable and more dynamic. This aligns with a broader idea in the literature that psychedelics can loosen certain fixed patterns of brain activity, causing information processing to occur differently than in the normal waking state.

For therapy, this is conceptually interesting, because many psychological problems are precisely characterized by rigidity: ingrained beliefs, automatic avoidance patterns, or repetitive emotional scripts. The research does not show that psilocybin “solves” this, but it does suggest that the acute state may be accompanied by measurable changes in brain dynamics that, in some people, are associated with later psychological shifts.

From experience to effect: insight as a possible link

The study reported increases in cognitive flexibility, psychological insight, and well-being after one month. In themselves, these are broad concepts. “Well-being” can refer to mood, a sense of purpose, or general psychological health. “Insight” can range from recognizing patterns in relationships to understanding one’s own emotions differently. “Cognitive flexibility” often concerns the ability to switch between perspectives or strategies.

A striking detail is the chain described by the researchers: higher brain tropism during the acute experience was associated with greater psychological insight the following day, and that insight was subsequently associated with greater well-being after one month. This is not proof of cause and effect, but it is an indication of a possible process: the quality or intensity of the acute brain dynamics may say something about the likelihood of subsequent psychological “lingering effects.”.

This is familiar to therapy: insight in itself is rarely enough. The question is whether an insight can be integrated into daily life. In the classical therapy world, this is done through reflection, practice, and new experiences. In psychedelic therapy contexts, this is often referred to as “integration.” This study underscores that it is not only about the acute experience but also about what happens afterward, although this specific article did not investigate an extensive integration program.

White matter and connectivity: interesting signals, but interpret with caution

With DTI, the researchers found evidence of changes in white matter tracts between the prefrontal cortex and subcortical areas, including connections to the striatum and the thalamus. These changes were visible one month after 25 mg, but not after 1 mg.

This might easily sound like “neuroplasticity,” but nuance is essential here. DTI is sensitive to microstructural properties, but the significance of small changes is not always unambiguous. The authors therefore emphasize themselves that these are exploratory findings and that interpretation must be cautious. For example, we do not know whether these are stable changes, or how they relate to functioning outside the test environment.

In resting-state fMRI, long-term changes in functional connectivity were also largely absent. This is interesting because it shows that not every brain measure necessarily reveals lasting shifts after a single experience, certainly not in healthy participants. However, there was a correlation between a decrease in “network modularity” and an increase in well-being. Lower modularity roughly means that brain networks are less strictly separated and potentially work together in a more integrated manner. This has also been observed in some clinical studies, but again: this study does not prove a therapeutic effect, partly because the participants were not part of the clinical population.

What this means for therapy: three practical lessons

1) Measurable change is not the same as clinical improvement.
The presence of changes in EEG, DTI, or self-report does not automatically mean that a condition is being treated. Ultimately, therapy is about functioning, symptom burden, and quality of life, and that requires different research questions and larger studies.

2) The acute experience is possibly a “window”, not an endpoint.
The potential role of insight as a link towards well-being aligns with the idea that the value in therapy lies not only in experiencing an intense event, but in processing it. In a therapeutic approach, this typically involves preparation, guidance, and integration. Exactly how this should be implemented varies by setting and person, and is still a subject of scientific development.

3) Context and set-setting remain crucial.
This study took place in a controlled research context. This is relevant because expectations, environment, guidance, and safety all contribute to how someone experiences a psychedelic experience. Outside of research, that control is often lacking. This does not mean that proper guidance is impossible, but rather that the assumption that "same substance, same effect" is too simplistic.

Safety and realistic expectations

Although this article is primarily mechanistic, it indirectly touches upon safety: it demonstrates that psychedelics have powerful, measurable effects on the brain and the experience. That is precisely why caution is necessary. Risks may include mental overload, anxiety-provoking experiences, unsafe conditions, or underestimating aftercare and integration. Which risks are relevant varies greatly by person and situation and cannot be “ticked off” in a general sense.

It is also important to keep the context clear: psilocybin and MDMA-assisted therapy are subjects of scientific research. MDMA sessions can currently only be discussed within scientific research or in clinical practice via harm reduction. In a harm reduction context, the emphasis is on risk mitigation, proper preparation, careful guidance, and aftercare, without claims that it constitutes a medical treatment.

Conclusion

This exploratory study shows that an initial high dose of psilocybin in healthy, psychedelic-naive participants can be associated with clear acute changes in brain dynamics, and with indications of changes in insight and well-being up to a month later. At the same time, the interpretation remains cautious: the sample size is small, the participants had no clinical diagnosis, and the measured changes are not evidence of therapeutic efficacy.

What psilocybin research can primarily teach us about therapy is that change may be linked to processes such as flexibility, insight, and integration. This makes it a relevant field of research, but also a subject that calls for realistic expectations, proper context, and an emphasis on safety. Those wishing to explore guided sessions within a harm-reduction framework can find more information via sign up for an MDMA session, where it is important to keep the distinction between research, experience, and practical guidance clear.

MDMA THERAPY